HOME > 教室紹介 > 診療・研究内容 > (2)循環グループ

教室紹介

教室紹介

診療・研究内容

(2)循環グループ

循環グループ
年間約120例の「肺高血圧症」、約260例の「慢性心不全」の心臓カテーテル検査を行い(詳細はこちらからご覧になれます)、それらの疾患における臨床研究を行っている。

図:診療実績(2016)診療実績

1. 肺高血圧症

肺高血圧症は、進行性の肺血管抵抗上昇および肺動脈圧上昇を特徴とする予後不良な疾患である。最近様々な治療薬が開発され、一定の効果をあげているものの、未だにその治療効果は不十分である。我々は、これまで肺高血圧症に対するRhoキナーゼ経路の役割を検討してきており、Rhoキナーゼ阻害薬であるファスジルが、動物モデルに対して血行動態的変化および組織学的変化に対し有効であることを明らかにし(J Cardivasc Pharmacol 2006・2007など)、さらに臨床研究においても、肺高血圧症患者においてファスジルが肺血管抵抗を減少させる急性効果を有することも明らかにした(Heart 2005)。今後、薬剤の開発を含め、肺高血圧症患者におけるファスジルの慢性効果を検討する予定であり、また既存の治療の有効性に関する臨床的因子の検討も行っている。

肺高血圧症治療への新たな取り組み

2. 心血管病

心血管病は、高血圧・高脂血症などの危険因子の出現に始まり、動脈硬化症の合併を経て、心不全に至り、死を迎える経路をたどる。動脈硬化症は心筋梗塞、狭心症、脳梗塞といった虚血性疾患の原因となるだけでなく、血管機能低下を来たし慢性心不全における血行動態破綻の一因となるため、その治療が心血管死の予防となり得る。
我々はこれまで動脈硬化と炎症に関する基礎・臨床研究を行ってきており(Circulation 1997・2001, JACC 2003など)、動脈硬化症に対する治療戦略としては、量的改善のみならず質的改善が重要であると考えている。その質的改善には血管内皮機能の改善および粥状動脈硬化症におけるプラークの安定化が重要であり、抗炎症・マクロファージの活性化抑制・コラーゲン代謝の改善が重要な役割を果たすことを明らかにし(Circulation 2001・2004)、血管攣縮などの血管機能低下にはRhoキナーゼ経路が関与していることを明らかにしてきた(ATVB 2004, J Cardivasc Pharmacol 2004・2007など)。
慢性心不全には高血圧・高脂血症・糖尿病といった危険因子が慢性心不全発症に大きく関与していることが明らかとなっているが、メタボリック症候群の役割は未だ明らかではない。現在、全国多施設において慢性心不全におけるメタボリック症候群の役割を前向きに検討している(厚生労働科研採択研究)。また慢性心不全の約3割に中枢型睡眠時無呼吸を認め、酸素療法が有効であることも示している。
急性心不全はあらゆる心臓病の末期症状として発症する。急性心不全の治療としては血管拡張薬・利尿薬が中心となることが多く、必要に応じ挿管・強心薬・メカニカルサポートにて加療する。その際、臓器保護を念頭に加療を行うべきであり、腎機能が独立したその予後規定因子であることから、多施設研究で、心不全急性期の腎機能に焦点を当てた臨床研究を行っている。

慢性心不全に対する基礎・臨床研究(1)

図3

主な研究業績 (2000年以降)
2017年
  1. Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Konno R, Miyata S, Nochioka K, Satoh K, Shimokawa H. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension -Long-term effects and procedure-related complications- Eur Heart J. (in press)
  2. Godo S, Shimokawa H. Recent highlights of ATVB: Endothelial functions. Arterioscler Thromb Vasc Biol. (in press)
  3. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Numano K, Elias-Al-Mamun M, AbdulHai Siddique MAH, Sunamura S, Nogi M, Suzuki K, Miyata S, John Morser J, Shimokawa H. Activated TAFI promotes the development of chronic thromboembolic pulmonary hypertension - A possible novel therapeutic target - Circ Res. 120:1246-1262,2017.PDF
  4. Onose T, Sakata Y, Nochioka K, Miura M, Yamauchi T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Miyata S, Takahashi J, Shimokawa H; the CHART-2 Investigators. Sex differences in post-traumatic stress disorder in cardiovascular patients after the Great East Japan Earthquake -A report from the CHART-2 Study- Eur Heart J QCCO. (in press)
  5. Satoh K, Sugimura K, Shimokawa H. Rho-kinase as a therapeutic target for pulmonary hypertension. In: Fukumoto Y (ed), Diagnosis and Treatment of Pulmonary Hypertension. From Bench to Bedside, pp. 67-76. Springer Nature, Singapore, 2017.
  6. Ohtsuki T, Satoh K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Yaoita N, Aoki T, Tatebe S, Sugimura K, Takahashi J, Miyata S, Shimokawa H. Prognostic impacts of plasma levels of cyclophilin A in patients with coronary artery disease. Arterioscler Thromb Vasc Biolol. 37:685-693,2017.PDF
  7. Aoki T, Shimokawa H. Earthquake and hypertension-from acute to chronic phase after the Great East Japan Earthquake. J Xiangya Med. 2:9,2017.PDF
  8. Godo S, Shimokawa H. Divergent roles of endothelial nitric oxide synthases system in maintaining cardiovascular homeostasis. Free Radical Biology & Medicine. 109:4-10,2017.PDF
2016年
  1. Aoki T, Sugimura K, Nochioka K, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Miyata S, Satoh K, Shimokawa H. Effects of balloon pulmonary angioplasty on oxygenation in patients with chronic thromboembolic pulmonary hypertension - Importance of intra-pulmonary shunt - Circ J. 80:2227-2234,2016.PDF
  2. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. (Editorial) ESC Heart Failure. 3:145-151,2016. PDF
  3. Kozu K, Suzuki H, Nishiyama S, Yaoita N, Yamamoto S, Tatebe S, Miura M, Aoki T, Hao K, Matsumoto Y, Sugimura K, Aoki M, Shimokawa H. Multiple sclerosis lesion in the medulla oblongata in a patient with takotsubo cardiomyopathy. Int J Cardiol. 8:980-981,2016.PubMed
  4. Kudo S, Satoh K, Nogi M, Suzuki K, Sunamura S, Omura J, Kikuchi N, Kurosawa R, Satoh T, Minami T, Ikeda S, Shimokawa H. SmgGDS as a crucial mediator of the inhibitory effects of statins on cardiac hypertrophy and fibrosis. -Novel mechanism of the pleiotropic effects of statins- Hypertension. 67:878-889,2016.PDF
  5. Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H ; CHART-2 Investigators. Prognostic impact of loop diuretics in patients with chronic heart failure -Effects of addition of renin-angiotensin-aldosterone system inhibitors and β-blockers. Circ J. 80:1396-1403,2016.PDF
  6. Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Otsuki T, Kozu K, Numano K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Miyata S, Hoshikawa Y, Okada Y, Shimokawa H. Protective roles of endothelial AMP-activated protein kinase against hypoxia-induced pulmonary hypertension in mice. Circ Res. 119:197-209,2016.PDF
  7. Sato H, Ota H, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Satoh K, Takase K, Shimokawa H. Balloon pulmonary angioplasty improves biventricular functions and pulmonary flow in chronic thromboembolic pulmonary hypertension. Circ J. 80:1470-1477,2016.PDF
  8. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res. 118:352-366,2016.PDF
  9. Sugimura K, Satake H, Shimokawa H. Respiratory therapy in chronic heart failure patients complicated with sleep-disordered breathing: potential study bias. (Authors’ reply) Circ J. 80:1486-1487,2016.PubMed
  10. Sugimura K, Shinozaki T, Fukui S, Ogawa H, Shimokawa H. End-tidal CO2 tension is predictive of effective nocturnal oxygen therapy in patients with chronic heart failure and central sleep apnea. Tohoku J Exp Med. 239:39-45,2016.PDF
  11. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Furukawa K, Arai H, Fukumoto Y, Taki Y, Shimokawa H. Hippocampal blood flow abnormality associated with depressive symptoms and cognitive impairment in patients with chronic heart failure. Circ J. 80:1773-1780,2016.PDF
  12. Suzuki K, Satoh K, Ikeda S, Sunamura S, Otsuki T, Satoh T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Numano K, Sugimura K, Aoki T, Tatebe S, Miyata S, Mukherjee R, Spinale FG, Kadomatsu K, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice. Arterioscler Thromb Vasc Biol. 36:636-646,2016.PDF
  13. Suzuki H, Sugimura K, Tatebe S, Aoki T, Shimokawa H. Chronic thromboembolic pulmonary hypertension and schizophrenia. Int J Cardiol. 207:363-364,2016.PubMed
  14. Takagi H, Hideki Ota H, Sugimura K, Otani K, Tominaga J, Aoki T, Tatebe S, Miura M, Yamamoto S, Sato H, Nobuhiro Yaoita N, Suzuki H, Shimokawa H, Takase K. Dual-energy CT to estimate clinical severity of chronic thromboembolic pulmonary hypertension: Comparison with invasive right heart catheterization. Eur J Radiol. 85:1574-1580,2016.PubMed
  15. Tatebe S, Sugimura K, Aoki T, Miura M, Nochioka K, Miyamichi-Yamamoto S, Yaoita N, Suzuki H, Sato H, Satoh K, Fukumoto Y, Shimokawa H. Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ J. 80:980-988,2016.PDF
  16. Tsutsui H, Momomura S, Yamashina A, Ogawa H, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Ako J, Inomata T, Tanaka T, Kawasaki Y, on behalf of the study investigators. Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure -A randomized, double-blind, placebo-controlled phase II study- Circ J. 80:668-676,2016.PDF
  17. Yamamoto S, Suzuki H, Sugimura K, Tatebe S, Aoki T, Miura M, Yaoita N, Sato H, Kozu K, Ota H, Takanami K, Takase K, Shimokawa H. Focal reduction in cardiac 123I-metaiodobenzylguanidine uptake in patients with Anderson-Fabry disease. Circ J. 80:2550-2551,2016.PDF
  18. Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H. Thrombin-activatable fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Arterioscler Throm Vasc Biol. 36:1220-1229,2016.PubMed
  19. Yaoita N, Satoh K, Shimokawa H. Novel therapeutic targets of pulmonary hypertension. (Review) Arteriosclr Thromb Vasc Biol. 2016;36:e97-e102. DOI: 10.1161/ATVBAHA.116.308263.PDF
  20. Yoshida M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, Shirota Y, Sugimura K, Fujii H, Shimokawa H, Harigae H. Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheumatic Dis. 19:87-94,2016.PubMed
2015年
  1. Ito K, Shimokawa H. The future of non-invasive angiogenic therapy using acoustic waves. Circ J. 79:1906-1907,2015.
  2. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H, the CHART-2 investigators. Prognostic impact of diabetes mellitus in chronic heart failure according to presence of ischemic heart disease. -With special reference to nephropathy- Circ J. 79:1764-1772,2015.PDF
  3. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of statin use in patients with heart failure with preserved ejection fraction -A report from the CHART-2 Study- Circ J. 79:574-582,2015.PDF
  4. Onose T, Nochioka K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Miyata S, Takahashi J, Shimokawa H. Predictors and prognostic impact of post-traumatic stress disorder after the Great East Japan Earthquake in patients with cardiovascular disease -- Report from the CHART-2 Study -- Circ J. 79:664-667,2015.PDF
  5. Ota H, Sugimura K, Miura M, Shimokawa H. 4D flow MRI visualizes drastic change of vortex flow in the main pulmonary artery after percutaneous transluminal balloon angioplasty in a patient with chronic thromboembolic pulmonary hypertension. Eur Heart J. 36:1630,2015.PubMed
  6. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H, on behalf of the SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure. -The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) Trial- Eur Heart J. 36:915-923,2015. PubMed
  7. Satake H, Fukuda K, Sakata Y, Miyata S, Nakano M, Kondo M, Hasebe Y, Segawa M, Shimokawa H, the CHART-2 Investigators. Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure. -A report from the CHART-2 Study- Circ J. 79:381-390,2015.PDF
  8. Satake H, Sugimura K, Fukumoto Y, Fukuda K, Nakano M, Kondo M, Fukui S, Ogawa H, Shinozaki T, Shimokawa H. Effects of respiratory therapy on the prognosis of chronic heart failure patients complicated with sleep-disordered breathing -A pilot efficacy trial- Circ J. 80:130-138,2015.PubMed
  9. Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onode T, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H, the CHART-2 investigators. Comprehensive risk stratefification of Japanese patients with aortic stenosis. -A proposal of a new risk score from the CHART-2 Study- Circ J. 79:1631-1638,2015.PDF
  10. Satoh K, Shimokawa H. Cyclophilin A: Novel biomarker for oxidative stress and cardiovascular diseases. In: Preedy VR, Patel VB (eds), General Methods in Biomarker Research and Their Applications, pp. 405-438, Springer Reference, London, 2015.
  11. Satoh K, Kikuchi N, Kurosawa R, Shimokawa H. PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circ Res. 116:1098-1100,2015.PubMed
  12. Satoh K. Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med. 235:1-15,2015.PubMed
  13. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 17:884-892,2015PubMed
  14. Shimokawa H, Satoh K. 2015 ATVB Plenary lecture: Translational research on Rho-kinase in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 35:1756-1769,2015.PDF
  15. Shimokawa H, Satoh K. Light and dark of reactive oxygen species for vascular function. J Cardiovasc Pharmacol. 65:412-418,2015.PubMed
  16. Takahashi J, Shimokawa H. Earthquake, cardiovascular diseases and implications for public health. In Watson RR, Tabor JA, Ehiri JE, Preedy (eds.), Handbook of Public Health in Natural Disasters, pp.309-333, Wageningen Academic Publishers, The Netherlands, 2015.
  17. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H, the CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan -A report from the CHART Studies- Circ J. 79:2396-2407,2015.PDF
  18. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H; the CHART-2 Investigators, Improved long-term prognosis of patients with dilated cardiomyopathy with implementation of evidenced-based medications. -A report from the CHART Studies- Circ J. 79:1332-1341,2015.PDF
  19. Yamauchi T, Sakata Y, Takada T, Nochioka K, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Miyata S, Shimokawa H. Prognostic impacts of anemia in patients with chronic heart failure with a special reference to clinical background -A report from the CHART-2 Study- Circ J. 79:1984-1993,2015PubMed
2014年
  1. Al-Mamun ME, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J. 78:967-976,2014.PDF
  2. Dai Z, Sugimura K, Fukumoto Y, Tatebe S, Miura Y, Nochioka K, Aoki T, Miyamichi-Yamamoto S, Yaoita N, Satoh K, Shimokawa H. Visualization of Complete Regression of Pulmonary Arterial Remodeling on Optical Coherence Tomography in a Patient With Pulmonary Arterial Hypertension. Circ J. 78:2771-2773,2014.PDF
  3. Hao K, Takahashi J, Aoki T, Miyata S, Ito K, Sakata Y, Shimokawa H. Factors influencing the occurrence of cardiopulmonary arrest in the Great East Japan Earthquake Disaster. Intn'l J Cardiol. 177:569-572,2014.PubMed
  4. Nergui S, Fukumoto Y, Do.e Z, Nakajima S, Shimizu T, Ikeda S, Elias-Al-Mamun M, Shimokawa H. Role of eNOS and collagen metabolism in right ventricular remodeling due to pulmonary hypertension. Circ J. 78:1465-1474,2014.PDF
  5. Onishi Y, Sugimura K, Ohba R, Imadome K, Shimokawa H, Harigae H. Resolution of chronic active EBV infection and coexisting pulmonary arterial hypertension after cord blood transplantation. Bone Marrow Transplantation. 49:1343-1344,2014.PubMed
  6. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 1:4-25,2014.PDF
  7. Satoh K, Satoh T, Kikuchi N, Omura J, Kurosawa R, Suzuki K, Sugimura K, Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Fukumoto Y, Minami T, Miyata S, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. Circ Res. 115:738-750,2014.PDF
  8. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: Still need for next-generation biomarkers for remote future cardiovascular events. Eur Heart J. 35:1776-1778,2014. (Editorial)PubMed
  9. Shimokawa H. 2014 William Harvey Lecture. Importance of coronary vasomotion abnormalities -From bench to bedside- Eur Heart J. 35:3180-3193,2014.PubMed
  10. Shimokawa H, Satoh K. Recent Highlights of ATVB: Vascular function. Arteriosclr Thromb Vasc Biol. 34:2359-2362,2014.
  11. Suzuki H, Matsumoto Y, Kaneta T, Sugimura K, Takahashi J, Fukumoto Y, Takahashi S, Shimokawa H. Evidence for brain activation in patients with takotsubo cardiomyopathy. Circ J. 78:256-258,2014.PDF
  12. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H, on behalf of the CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction. -A report from the CHART-2 Study- Eur J Heart Fail. 16:309-316,2014.PubMed
  13. Tsutsui M, Shimokawa H, Tanimoto A, Yanagihara N, Otsuji Y. Roles of nitric oxide synthases in arteriosclerotic vascular disease-Insights from murine genetic models- J Clin Exp Cardiol. 5: 318. doi:10.4172/2155-9880.1000318,2014.PDF
  14. Yamaki S, Ando M, Fukumoto Y, Higuchi Y, Kaneko K, Maeda K, Shimokawa H. Histopathological examination by lung biopsy for the evaluation of operability and postoperative prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 78:476-482,2014.PDF
  15. Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura M, Tatebe S, Aoki T, Yamamoto S, Satoh K, Kimura T, Shimokawa H, Horiuchi H. Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension (CTEPH). Arterioscler Thromb Vasc Biol. 34:2486-2494,2014.PubMed
2013年
  1. Aoki T, Takahashi J, Fukumoto Y, Yasuda S, Ito K, Miyata S, Shinozaki T, Inoue K, Yagi T, Komaru T, Katahira Y, Obata A, Hiramoto T, Sukegawa H, Ogata K, Shimokawa H. Effect of the Great East Japan Earthquake Disaster on cardiovascular diseases -A report from the 10 hospitals in the Disaster area- Circ J. 77:490-493,2013.PDF
  2. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, Takeda Y, Adachi T, Osanai S, Tanabe N, Inoue T, Kubo A, Ota Y, Fukuda K, Nakano T, Shimokawa H. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension -A pilot efficacy trial- Circ J. 77:2619-2625,2013.PDF
  3. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shiba N, Shimokawa H, on behalf of the CHART-2 Investigators. Usefulness of combined risk stratification with Heart rate and systolic blood pressure in the management of chronic heart failure -A report from the CHART-2 Study- Circ J. 77:2954-2962,2013.PDF
  4. Miura M, Sakata Y, Nochioka K, Takahashi J, Takada T, Miyata S, Hiramoto T, Inoue K, Tamaki K, Shiba N, Shimokawa H. Prognostic impact of blood urea nitrogen changes during hospitalization in patients with acute heart failure syndrome. Circ J. 77:1221-1228,2013.PDF
  5. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shiba N, Shimokawa H. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: a report from the CHART-2 Study. Circ J. 77:2318-2326,2013.PDF
  6. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 77:2209-2217,2013.PubMed
  7. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Aoki T, Nochioka K, Tatebe S, Miyamichi-Yamamoto S, Shimizu T, Osaki S, Takagi Y, Tsuburaya R, Ito Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 77:447-455,2013.PDF
  8. Sugimura K, Fukumoto Y, Miura Y, Nochioka K, Miura M, Tatebe S, Aoki T, Satoh K, Yamamoto S, Yaoita N, Shimokawa H. Three-dimensional-optical coherence tomography imaging of chronic thromboembolic pulmonary hypertension. Eur Heart J. 34:2121,2013.PubMed
  9. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Miura M, Yamamoto S, Yaoita N, Satoh K, Shimokawa H. Optical coherence tomography is superior to intravascular ultrasound for diagnosis of distal-type chronic thromboembolic pulmonary hypertension. Circ J. 77:1081-1083,2013.PDF
2012年
  1. Aoki T, Fukumoto Y, Yasuda S, Sakata Y, Ito K, Takahashi J, Miyata S, Tsuji I, Shimokawa H. The Great East Japan Earthquake Disaster and cardiovascular diseases. Eur Heart J. 33:2796-2803,2012.PubMed
  2. Dai Z, Aoki T, Fukumoto Y, Shimokawa H. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol. 60:416-421,2012.PubMed
  3. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 33:436-443,2012.PubMed
  4. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, Shimokawa H, on behalf of the CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail. 14:367-376,2012.PubMed
  5. Nakamura Y, Shimizu T, Fukumoto Y, Sugimura K, Ito S, Fujishima F, Oikawa M,Watanabe M, Shimokawa H, Sasano H. A case of angiosarcoma arising in trunk of the right pulmonary artery clinically simulating pulmonary thromboembolism. World J Oncology. 3:119-123,2012.PDF
  6. Nakano M, Kondo M, Wakayama Y, Kawana A, Hasebe Y, Shafee MA, Fukuda K, Shimokawa H. Increased Incidence of tachyarrhythmias and heart failure hospitalization in patients implanted with cardiac devices after the Great East Japan Earthquake Disaster. Circ J. 76:1283-1285,2012.PDF
  7. Nochioka K, Tanaka S, Miura M, Zhulanqiqige DE, Fukumoto Y, Shiba N, Shimokawa H. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J. 76:2023-2030,2012.PDF
  8. Shiba N, Shimokawa H. Prospective care of heart failure in Japan: Lessons from CHART Studies. EPMA. 2:425-438,2012.PDF
  9. Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, Tatebe S, Miyamichi-Yamamoto S, Shimokawa H. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 76:485-488,2012.PDF
  10. Sumiyoshi A, Suzuki H, Shimokawa H, Kawashima R. Neurovascular uncoupling under mild hypoxic hypoxia: an EEG-fMRI study in rats. J Cereb Blood Flow Metab. 32:1853-1858,2012.PubMed
  11. Tatebe S, Fukumoto Y, Sugimura K, Miyamichi-Yamamoto S, Aoki T, Miura Y, Nochioka K, Satoh K, Shimokawa H. Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. Circ J. 76:1235-1244,2012.PDF
2011年
  1. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure -Comparison between preserved and reduced ejection fraction heart failure- Circ J. 75:2605-2613,2011.PDF
  2. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura U, Tatebe S, Nochioka K, Aoki T, Do.e Zhulanqiqige, Shimokawa H. Intensive immunospuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 75:2668-2674,2011.PubMed
  3. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis J, Sparks JD, Berk BC. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 208:53-66,2011.PubMed
  4. Rabieyousefi M, Soroosh P, Satoh K, Date1 F, Ishii N, Yamashita M, Oka M, McMurtry IF, Shimokawa H, Nose M, Sugamura K, Ono M. Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension. BMC Immunology. 12:67-79,2011.PDF
  5. Satoh K, Berk BC, Shimokawa H. Vascular-derived reactive oxygen species for homeostasis and diseases. Nitric Oxide. 25:211-215,2011. (Review)PubMed
  6. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol. 301:287-296,2011.PubMed
  7. Satoh K, Nigro P, Zeidan A, Soe NN, Jaffré F, Oikawa M, O'Dell MR, Cui Z, Menon P, Lu Y, Mohan A, Yan C, Blaxall BC, Berk BC. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 31:1116-1123,2011.PubMed
  8. Wang W, Kagaya Y, Asaumi Y, Fukui S, Takeda M, Shimokawa H. Protective effects of recombinant human erythropoietin against pressure overload-induced left ventricular remodeling and premature death in mice. Tohoku J Exp Med. 225:131-143,2011.PubMed
2010年
  1. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels. 25:144-149,2010.PubMed
  2. Kikuchi Y, Ito K, Ito Y, Shiroto T, Tsuburaya R, Aizawa K, Hao K, Fukumoto Y, Takahashi J, Takeda M, Nakayama M, Yasuda S, Kuriyama S, Tsuji I, Shimokawa H. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J. 74:589-591,2010.PDF
  3. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, Takagi A, Matsusaka H, Tsutsumi T, Yamada A, Kinugawa S, Asakura M, Okamatsu S, Tsutsui H, Daida H, Matsuzaki M, Tomoike H, Shimokawa H. Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J. 74:2612-2621,2010.PDF
  4. Miura Y, Fukumoto Y, Sugimura K, Oikawa M, Nakano M, Tatebe S, Miyamichi S, Satoh K, Shimokawa H. Identification of new prognostic factors of pulmonary hypertension. Circ J. 74:1965-1971,2010.PubMed
  5. Nakano M, Fukumoto Y, Satoh K, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc Res. 79:212-220,2010.PubMed
  6. Nigro P, Abe JI, Woo CH, Satoh K, McClain C, O'Dell MR, Fujiwara K, and Berk BC. PKCζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood 116:1971-1979,2010.PubMed
  7. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, Urata H, Shimokawa H, Minatoguchi S. Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis. Circ J. 74:1943-1950,2010.PDF
  8. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: A mechanistic linkage by cyclophilin A. Antioxidants & Redox Signaling. 12:675-682,2010.PubMed
  9. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circulation J. 74:2249-2256,2010. (review)PubMed
  10. Sugimura K, Fukumoto Y, Nawata J, Wang H, Onoue N, Tada T, Shirato K, Shimokawa H. Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats -Implication for the pathogenesis of hypertensive vascular disease-. Tohoku J Exp Med. 222:201-210,2010.PubMed
  11. Tatebe S, Fukumoto Y, Sugimura K, Nakano M, Miyamichi S, Satoh K, Oikawa M, Shimokawa H. Optical coherence tomography as a novel diagnostic tool for distal type chronic thromboembolic pulmonary hypertension. Circ J. 74:1742-1744,2010.PubMed
2009年
  1. Do E Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H. Evidence for Rho-Kinase Activation in Patients With Pulmonary Arterial Hypertension. Circ J. 73:1731-1739,2009.PubMed
  2. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Shinozaki T, Kagaya Y, Watanabe J, Shimokawa H. Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of the renin-angiotensin system in hypertensive rats. Hypertens Res. 32:472-480,2009.PubMed
  3. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J. 73:361-370,2009.PDF
  4. Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovascular Res. 81:226-234,2009.PubMed
  5. Satoh K, Nigro P, Matoba T, O'Dell MR, ---, Illig KA, Berk BC. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nature Medicine. 15:649-656,2009.PubMed
2008年
  1. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol. 51:317-326,2008.PubMed
  2. Fukumoto Y, Yasuda S, Ito A, Shimokawa H. Prognostic effects of benidipine in patients with vasospastic angina: Comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol. 51:253-257,2008.PubMed
  3. Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, Takahashi S. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol. 191:862-869,2008.PubMed
  4. Kerwin WS, Liu F, Yarnykh V, Underhill H, Oikawa M, Yu W, Hatsukami TS, Yuan C. Signal features of the atherosclerotic plaque at 3.0 Tesla versus 1.5 Tesla: impact on automatic classification. J Magn Reson Imaging. 28:987-995,2008.PubMed
  5. Kerwin WS, Oikawa M, Yuan C, Jarvik GP, Hatsukami TS. MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med. 59:507-514,2008.PubMed
  6. Oi K, Fukumoto Y, Ito K, Uwatoku T, Abe K, Hizume T, Shimokawa H. Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. Tohoku J Exp Med. 214:151-158,2008.PubMed
  7. Onoue N, Nawata J, Tada T, Zhulanqiqige D, Wang H, Sugimura K, Fukumoto Y, Shirato K, Shimokawa H. Increased static pressure promotes migration of vascular smooth muscle cells: Involvement of the Rho-kinase pathway. J Cardiovasc Pharmacol. 51:55-61,2008.PubMed
  8. Satoh K, Berk BC. Circulating smooth muscle progenitor cells: novel players in plaque stability. Cardiovasc Res. 77:445-447,2008.PubMed
  9. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, Mohan A, Pan S, Li L, Jin ZG, Yan C, Abe J, Berk BC. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation. 117:3088-3098,2008.PubMed
  10. Shimokawa H, Ito K, Fukumoto Y, Yasuda S. Extracorporeal cardiac shock wave therapy for ischemic heart disease. Shock Waves. 17:449-455,2008.
  11. Tada T, Nawata J, Wang H, Onoue N, Zhulanqiqige D, Ito K, Sugimura K, Fukumoto Y, Shimokawa H. Enhanced pulsatile pressure accelerates vascular smooth muscle migration -implications for atherogenesis of hypertension-. Cardiovasc Res. 80:346-353,2008.PubMed
  12. Underhill HR, Yarnykh VL, Hatsukami TS, Wang J, Balu N, Hayes CE, Oikawa M, Yu W, Xu D, Chu B, Wyman BT, Polissar NL, Yuan C. Carotid plaque morphology and composition: initial comparison between 1.5- and 3.0-T magnetic field strengths. Radiology. 248:550-560,2008.PubMed
  13. Underhill HR, Yuan C, Terry JG, Chen H, Espeland MA, Hatsukami TS, Saam T, Chu B, Yu W, Oikawa M, Takaya N, Yarnykh VL, Kraft R, Carr JJ, Maldjian J, Tang R, Crouse JR 3rd. Differences in carotid arterial morphology and composition between individuals with and without obstructive coronary artery disease: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 10:31,2008.PubMed
  14. Yuan C, Oikawa M, Miller Z, Hatsukami T. MRI of carotid atherosclerosis. J Nucl Cardiol. 15:266-275,2008. (Review)PubMed
2007年
  1. Fukumoto Y, Kishi T, Tsutsui H, Yamada A, Okamatsu S, Takeshita A. Elevated serum C-reactive protein levels as a predictive indicator for subsequent renal impairment in patients with acute heart failure. Tohoku J Exp Med. 213:361-368,2007.PubMed
  2. Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, Hirooka Y, Takeshita A, Shimokawa H. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol. 49:117-121,2007.PubMed
  3. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension. Expectation for Rho-kinase inhibitors. Tohoku J Exp Med. 211:309-320,2007.PubMed
  4. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 49:85-89,2007.PubMed
  5. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 100:662-669,2007.PubMed
  6. Saji K, Fukumoto Y, Suzuki J, Fukui S, Nawata J, Shimokawa H. Colchicine, a microtubule depolymerizing agent, inhibits myocardial apoptosis in rats. Tohoku J Exp Med. 213:139-148,2007.PubMed
  7. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-Kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 50:195-200,2007.PubMed
  8. Yamawaki T, Yamada A, Fukumoto Y, Kishi T, Sobashima A, Kuwata K, Nakamura R, Sekiya M, Ando H, Okamatsu S. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level. Fukuoka Igaku Zasshi. 98:260-269,2007.PubMed
2006年
  1. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol. 48:280-285,2006.PubMed
  2. Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, Takeshita A, Sunagawa K, Shimokawa H. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis. 17:63-70,2006.PubMed
  3. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, Ono M, Watanabe J, Shirato K, Ishii N, Sugamura K, Shimokawa H. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 113:1142-1450,2006.PubMed
2005年
  1. Eto Y, Shimokawa H, Fukumoto Y, Matsumoto Y, Morishige K, Kunihiro I, Kandabashi T, Takeshita A. Combination therapy with cerivastatin and nifedipine improves endothelial dysfunction after balloon injury in porcine coronary arteries. J Cardiovasc Pharmacol. 46:1-6,2005.PubMed
  2. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 91:391-392,2005.PubMed
  3. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J, Takahashi T, Nawata J, Ido T, Watanabe J, Shirato K. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol. 45:1849-1855,2005.PubMed
  4. Saji K, Sakuma M, Suzuki J, Takahashi T, Demachi J, Nawata J, Kitamukai O, Onoue N, Sugimura K, Tada T, Fukui S, Kagaya Y, Watanabe J, Shirato K. Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion. Circ J. 69:335-338,2005.PubMed
  5. Sun H, Fukumoto Y, Ito A, Shimokawa H, Sunagawa K. Coronary microvascular dysfunction in patients with microvascular angina: analysis by TIMI frame count. J Cardiovasc Pharmacol. 46:622-626,2005.PubMed
  6. Zhao Y, Fukumoto Y, Mohri M, Shimokawa H, Takeshita A. Impact of sex and age on coronary basal tone. Intern Med. 44:354-355,2005.PubMed
2004年
  1. Furukawa Y, Cole SE, Shah RV, Fukumoto Y, Libby P, Mitchell RN. Wild-type but not interferon-gamma-deficient T cells induce graft arterial disease in the absence of B cells. Cardiovasc Res. 63:347-356,2004.PubMed
  2. Fukumoto Y, Deguchi JO, Libby P, Rabkin-Aikawa E, Sakata Y, Chin MT, Hill CC, Lawler PR, Varo N, Schoen FJ, Krane SM, Aikawa M. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation. 110:1953-1959,2004.PubMed
  3. Inokuchi K, Ito A, Fukumoto Y, Matoba T, Shiose A, Nishida T, Masuda M, Morita S, Shimokawa H. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol. 44:275-277,2004.PubMed
  4. Ito A, Fukumoto Y, Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium Channel Blockers. J Cardiovasc Pharmacol. 44:480-485,2004.PubMed
  5. Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura KI, Shibata Y, Matsuda T, Takeshita A, Shimokawa H. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 24:181-186,2004.PubMed
  6. Wang H, Nawata J, Kakudo N, Sugimura K, Suzuki J, Sakuma M, Ikeda J, Shirato K. The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo. J Hypertens. 22:1323-1332,2004.PubMed
2003年
  1. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A, Cholesterol embolism study(CHEST) investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 42:211-216,2003.PubMed
  2. Miura S, Ohno I, Suzuki J, Suzuki K, Okada S, Okuyama A, Nawata J, Ikeda J, Shirato K. Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol. 42:174-181,2003.PubMed
2002年
  1. Aikawa M, Sugiyama S, Voglic SJ, Rabkin E, Fukumoto Y, Hill CC, Schoen FJ, Witztum JL, Libby P. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation. 106:1390-1396,2002.PubMed
  2. Fukumoto Y, Urabe Y, Kubo T, Kaku T, Egashira K, Shimokawa H, Takeshita A. Augmented vasodilator response to L-arginine after coronary angioplasty may attenuate restenosis. Heart Vessels. 16:171-174,2002.PubMed
  3. Kitamukai O, Sakuma M, Takahashi T, Nawata J, Ikeda J, Shirato K. Hemodynamic effects of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonary hypertension. Intern Med. 41:429-434,2002.PubMed
  4. Takahashi T, Sakuma M, Ikeda J, Nawata J, Demachi J, Kitamukai O, Shirato K. Effects and problems of continuous infusion of epoprostenol for patients with primary pulmonary hypertension. Intern Med. 41:784-788,2002.PubMed
2001年
  1. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:276-283,2001.PubMed
  2. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiommi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 103:993-999,2001.PubMed
  3. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 104:2525-2532,2001.PubMed
  4. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 6:738-741,2001.PubMed
2000年
  1. Kuga T, Shimokawa H, Hirakawa Y, Kadokami T, Arai Y, Fukumoto Y, Kuwata K, Kozai T, Egashira K, Takeshita A. Increased expression of L-type calcium channels in vascular smooth muscle cells at spastic site in a porcine model of coronary artery spasm. J Cardiovasc Pharmacol. 35:822-828,2000.PubMed

(文責:福本義弘)

このページのTOPへ